• Fresenius-controlled mAbxience signed a licensing, development, manufacturing, marketing deal with Sandoz for an emicizumab biosimilar candidate.
• mAbxience will develop and manufacture in GMP-certified plants in Spain, Argentina; Sandoz gets exclusive global marketing rights excluding Argentina, Uruguay, Paraguay.
• Project targets Hemlibra-referenced emicizumab for hemophilia A; reference market estimated at USD 5.7 billion.
• Transaction expands mAbxience’s rare-disease pipeline, strengthening its hemophilia A position while leveraging Sandoz’s global biosimilars commercial platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via PR Newswire (Ref. ID: GE51386) on September 19, 2026, and is solely responsible for the information contained therein.